P Valent

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. Valent P, Büsche G, Theurl I, Uras I, Germing U, Stauder R, et al. Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica. 2018;103:1593-1603 pubmed publisher
    ..The use and usefulness of established and novel erythropoiesis-stimulating agents for various indications, including myelodysplastic syndromes and other neoplasms, are also discussed. ..
  2. Valent P, Akin C. Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. J Allergy Clin Immunol Pract. 2019;7:1109-1114 pubmed publisher
    ..These criteria and assays may be useful in daily practice and help avoid unnecessary referrals and unjustified fears in patients. ..
  3. Eisenwort G, Sadovnik I, Schwaab J, Jawhar M, Keller A, Stefanzl G, et al. Identification of a leukemia-initiating stem cell in human mast cell leukemia. Leukemia. 2019;: pubmed publisher
    ..Characterization of MCL LSCs should facilitate their purification and should support the development of LSC-eradicating curative treatment approaches in this fatal type of leukemia. ..
  4. Gleixner K, Sadovnik I, Schneeweiss M, Eisenwort G, Byrgazov K, Stefanzl G, et al. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. Leuk Res. 2018;78:36-44 pubmed publisher
    ..Whether such cooperative TKI effects also occur in vivo in patients with drug-resistant CML, remains to be determined in forthcoming studies. ..
  5. Valent P, Kern W, Hoermann G, Milosevic Feenstra J, Sotlar K, Pfeilstöcker M, et al. Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. Int J Mol Sci. 2019;20: pubmed publisher
  6. Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, et al. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2019;7:1125-1133.e1 pubmed publisher
    ..Although validation is required, we anticipate that this algorithm will facilitate the management of patients with suspected MCAS. ..
  7. Valent P, Sotlar K, Horny H. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma. 2011;52:740-4 pubmed publisher
    ..Finally, CD30 may be considered as a potential target of antibody-based therapeutic intervention in advanced mast cell disorders. ..
  8. Uras I, Maurer B, Nebenfuehr S, Zojer M, Valent P, Sexl V. Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib. Int J Mol Sci. 2018;19: pubmed publisher
    ..Targeting synergistically acting vulnerabilities, with CDK6 being the common denominator, may represent a promising strategy to improve AML patient responses and to reduce the incidence of selection of resistance-inducing mutations. ..
  9. Valent P, Oude Elberink J, Górska A, Lange M, Zanotti R, van Anrooij B, et al. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. J Allergy Clin Immunol Pract. 2019;7:81-87 pubmed publisher
    ..Moreover, the core data set of the registry will be useful to establish multiparametric scoring systems through which prognostication and individualized management of patients with mastocytosis should improve in the foreseeable future. ..

More Information

Publications35

  1. Peter B, Cerny Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, et al. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. J Leukoc Biol. 2014;95:95-104 pubmed publisher
    ..Whether these drug effects can be translated to application in patients with advanced SM remains to be determined. ..
  2. Valent P, Berger J, Cerny Reiterer S, Peter B, Eisenwort G, Hoermann G, et al. Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Ann Hematol. 2015;94:223-31 pubmed publisher
    ..We propose that the chronic type of MCL with stable conditions, absence of organ damage, and a mature MC morphology is recognized as a distinct entity that should be distinguished from the acute variant of MCL. ..
  3. Mueller N, Wicklein D, Eisenwort G, Jawhar M, Berger D, Stefanzl G, et al. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood. 2018;: pubmed publisher
    ..Together, our data show that CD44 is a RAS-MEK/STAT5-driven MC invasion receptor that correlates with the aggressiveness of SM. Whether CD44 can serve as therapeutic target in advanced SM remains to be determined in forthcoming studies. ..
  4. Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, et al. Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. Wien Klin Wochenschr. 2018;130:517-529 pubmed publisher
    ..In the forthcoming years, the LBC ONC will concentrate on developing LSC-eradicating strategies, with special focus on LSC resistance, precision medicine and translation of LSC-eradicating concepts into clinical application. ..
  5. Blatt K, Menzl I, Eisenwort G, Cerny Reiterer S, Herrmann H, Herndlhofer S, et al. Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. Neoplasia. 2018;20:632-642 pubmed publisher
    ..Targeting of LSCs with specific antibodies or related immunotherapies may facilitate LSC eradication in ALL. ..
  6. Valent P, Sotlar K, Sperr W, Reiter A, Arock M, Horny H. Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. Leuk Res. 2015;39:1-5 pubmed publisher
    ..A recently proposed classification suggests that these cases are referred to as chronic MCL. In the present article, we discuss clinical, histopathological and morphological aspects of acute and chronic MCL. ..
  7. Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev. 2009;23:157-65 pubmed publisher
    ..In a group of patients, oncogenic tyrosine kinases (TK) such as FIP1L1/PDGFRA, can be employed as therapeutic targets by using imatinib or other TK-blocking agents. ..
  8. Sadovnik I, Hoelbl Kovacic A, Herrmann H, Eisenwort G, Cerny Reiterer S, Warsch W, et al. Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. Clin Cancer Res. 2016;22:2051-61 pubmed publisher
    ..Moreover, CD25 serves as a growth regulator of CML LSCs, which may have biologic and clinical implications and may pave the way for the development of new more effective LSC-eradicating treatment strategies in CML. ..
  9. Niklas N, Hafenscher J, Barna A, Wiesinger K, Pröll J, Dreiseitl S, et al. cFinder: definition and quantification of multiple haplotypes in a mixed sample. BMC Res Notes. 2015;8:422 pubmed publisher
    ..To our knowledge, this is the first software that enables researchers without extensive bioinformatic support to designate multiple haplotypes and how they constitute to a sample. ..
  10. Schulenburg A, Blatt K, Cerny Reiterer S, Sadovnik I, Herrmann H, Marian B, et al. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. J Hematol Oncol. 2015;8:16 pubmed publisher
    ..In the current article, we discuss new developments in the field of CSC research and whether these new concepts can be exploited in clinical practice in the future. ..
  11. Valent P, Bonnet D, Wohrer S, Andreeff M, Copland M, Chomienne C, et al. Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res. 2013;73:1037-45 pubmed publisher
    ..More precise molecular understanding of the different stem cell states thus distinguished should contribute to the development of more effective prognostic and therapeutic tools for cancer diagnosis and treatment. ..
  12. Almeida A, Prebet T, Itzykson R, Ramos F, Al Ali H, Shammo J, et al. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. Int J Mol Sci. 2017;18: pubmed publisher
    ..HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL. ..
  13. Sadovnik I, Herrmann H, Eisenwort G, Blatt K, Hoermann G, Mueller N, et al. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications. Exp Hematol. 2017;51:17-24 pubmed publisher
    ..In addition, it has been shown that CD25 serves as a negative growth regulator of CML LSCs. Here, we review the value of CD25 as a novel marker and potential drug target in CML LSCs. ..
  14. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo J, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12:767-75 pubmed publisher
  15. Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018;103:799-809 pubmed publisher
    ..Whether DCC-2618 is effective in vivo in patients with advanced systemic mastocytosis is currently under investigation in clinical trials. ..
  16. Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol. 2008;142:361-78 pubmed publisher
  17. Valent P, Akin C, Arock M, Brockow K, Butterfield J, Carter M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215-25 pubmed publisher
    ..Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets. ..
  18. Valent P, Hadzijusufovic E, Hoermann G, Füreder W, Schernthaner G, Sperr W, et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017;59:47-54 pubmed publisher
  19. Pleyer L, Valent P, Greil R. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?. Int J Mol Sci. 2016;17: pubmed publisher
    ..The current article also reviews molecular targets that play a role in such cellular interactions and possibilities to interfere with abnormal stem cell niche interactions by using specific targeted drugs. ..
  20. Valent P, Klion A, Horny H, Roufosse F, Gotlib J, Weller P, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130:607-612.e9 pubmed publisher
    ..The proposed novel criteria, definitions, and terminologies should assist in daily practice, as well as in the preparation and conduct of clinical trials. ..
  21. Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res. 2017;77:1261-1270 pubmed publisher
    ..i>Cancer Res; 77(6); 1261-70. ©2017 AACR. ..
  22. Rommer A, Steinleitner K, Hackl H, Schneckenleithner C, Engelmann M, Scheideler M, et al. Overexpression of primary microRNA 221/222 in acute myeloid leukemia. BMC Cancer. 2013;13:364 pubmed publisher
    ..Expression of some miRNAs is strongly regulated at the posttranscriptional level in AML. Pri-miR-221/222 represents a novel molecular marker and putative oncogene in this disease. ..
  23. Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny Reiterer S, Sadovnik I, et al. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML. Clin Cancer Res. 2014;20:3589-602 pubmed publisher
    ..CD52 is a novel prognostic NSC marker and a potential NSC target in a subset of patients with MDS and AML, which may have clinical implications and may explain clinical effects produced by alemtuzumab in these patients. ..
  24. Valent P, Gleich G, Reiter A, Roufosse F, Weller P, Hellmann A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012;5:157-76 pubmed publisher
    ..In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders. ..
  25. Valent P, Dahinden C. Role of interleukins in the regulation of basophil development and secretion. Curr Opin Hematol. 2010;17:60-6 pubmed publisher
    ..Some of the affected cytokine cascades, receptors, and signal transduction molecules may serve as targets of therapy in 'basophil activation disorders' in the future. ..
  26. Valent P, Akin C, Arock M, Bock C, George T, Galli S, et al. Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine. 2017;26:17-24 pubmed publisher
    ..This proposal should assist in the communication among patients, physicians and scientists, which is critical as genome-sequencing will soon be offered widely for early cancer-detection. ..